Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Chronic myeloid leukemia (CML) necessitates lifelong therapy due to persistent, drug-resistant leukemic stem cells (LSCs).
• Integrin-linked kinase (ILK) is a focal adhesion protein implicated in cell survival and cancer progression.

Purpose of the Study:

• To investigate the role of ILK in TKI resistance and LSC survival in CML.
• To evaluate ILK as a potential therapeutic target for overcoming TKI resistance in CML.

Main Methods:

• Transcriptome profiling of TKI-responsive and nonresponsive CML patient cells.
• Genetic and pharmacological inhibition of ILK.
• In vitro and in vivo assays to assess LSC survival and TKI sensitivity.
• RNA-sequencing and functional validation studies.

Main Results:

• ILK is highly expressed in TKI-nonresponsive CML cells and LSCs.
• ILK inhibition impaired survival of nonresponder cells and sensitized them to TKIs.
• ILK inhibition eradicated TKI-refractory LSCs in vitro and in vivo, sparing normal HSCs.
• ILK regulates mitochondrial oxidative metabolism in quiescent LSCs.

Conclusions:

• ILK is a critical mediator of TKI resistance and survival in CML LSCs.
• Targeting ILK offers a promising strategy for curative combination therapies in CML.
• ILK represents a novel therapeutic target for eradicating stem-cell-driven cancers.